The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants

Journal of Thoracic Oncology

Volumn 2, Issue 4, 2007, Pages 321-324

  Toyooka, Shinichi ^a,d   Uchida, Akiko ^a   Shigematsu, Hisayuki ^a   Soh, Junichi ^a   Ogino, Atsuko ^a   Takata, Minoru ^b   Kiura, Katsuyuki ^a   Ouchida, Mamoru ^a   Kosaka, Takayuki ^c   Aoe, Motoi ^a   Mitsudomi, Tetsuya ^c   Date, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

Author keywords

B RAF; Epidermal growth factor receptor; Epidermal growth factor receptor tyrosine kinase inhibitors; Gefitinib; Non small cell lung cancer

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RETINOIC ACID; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BINDING SITE; CANCER CHEMOTHERAPY; CASE REPORT; CODON; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; SENSITIVITY ANALYSIS; CELL CULTURE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 34247850951     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000263716.92191.be     Document Type: Article

References (15)

1. Rusch V, Baselga J, Cordon- CC, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 2001;53:2379-2385.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
4. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-262.
5. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
6. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
7. Kozuki T, Kiura K, Ueoka H, et al. Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung. Anticancer Res 2004;24:393-396.
8. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
9. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 2007;120:1239-1247.
10. Uchida A, Hirano S, Kitao H, et al. Activation of downstream EGFR signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Science 2007;98:357-363.
11. Uchida A, Matsuo K, Tanimoto M. APL during gefitinib treatment for non-small-cell lung cancer. N Engl J Med 2005;352:843.
12. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
13. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-319.
14. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
15. Tracy S, Mukohara T, Hansen M, et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004;64:7241-7244.